Loading...
Please wait, while we are loading the content...
Similar Documents
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors
| Content Provider | Semantic Scholar |
|---|---|
| Author | Pavel, Marianne E. Herder, Wouter W. De |
| Copyright Year | 2017 |
| Abstract | The landscape of treatment options in neuroendocrine tumors (NET) has changed in the last 5 years. Novel targeted drugs have been introduced and approved for distinct types of NET. Furthermore, with the first randomized trial on 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in midgut NET, not only is approval of this treatment awaited but also its more widespread use. Techniques and choices of radionuclides have changed over time as well as imaging tools. Recognition of well-differentiated NET G3 within the group of neuroendocrine neoplasms G3 has widened the spectrum of chemotherapeutic drugs used in this field. Even more so, it has become important to provide recommendations for daily clinical practice on how to safely use novel drugs, chemotherapeutic agents, and PRRT. The updated ENETS consensus guidelines for the standards of care in NET provide a tool to accurately assess the diagnosis of NET as well as practical recommendations for the use of surgery, and the different systemic therapeutic options that are available for the management of NET. |
| Starting Page | 193 |
| Ending Page | 195 |
| Page Count | 3 |
| File Format | PDF HTM / HTML |
| DOI | 10.1159/000457957 |
| PubMed reference number | 28190018 |
| Journal | Medline |
| Volume Number | 105 |
| Alternate Webpage(s) | https://www.karger.com/Article/Pdf/457957 |
| Alternate Webpage(s) | https://doi.org/10.1159/000457957 |
| Journal | Neuroendocrinology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |